The FDA is six months away from its scheduled ruling on Novo Nordisk's Type 2 diabetes drug liraglutide, but the agency said it will miss the deadline. According to this RPM Report analysis, the agency is missing more deadlines in general and may be extra cautious in this case, given the pancreatitis safety signal seen with Amylin Pharmaceuticals' exenatide.

Full Story:

Related Summaries